ClinicalTrials.gg

Program

APIM-containing Peptide ATX-101

Also written as “ATX-101”, “ATX101” and “ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)”.

Its studies are mostly in Pain, Postoperative · Ovarian Neoplasms, led by 4 companies.

Furthest: phase 3, since Apr 22, 201414 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie100 open or runningphase 3since Apr 22, 2014Jan 23, 2008none ahead
Allay Therapeutics20 open or runningphase 2since Feb 18, 2022Feb 18, 2022none ahead
Aurobac Therapeutics SAS10 open or runningphase 1since Jul 25, 2025Jul 25, 2025none ahead
THERAPIM PTY10 open or runningphase 2since Mar 4, 2021Mar 4, 2021none ahead

Also a collaborator on its studies: Novotech (Australia) Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2008First study: phase 1 study in HealthyNew to AbbVieAbbVie · NCT00618709 · 24 enrolled · United States
  2. Feb 3, 2009Phase 1 study in Characteristics of Subcutaneous FatAbbVie · NCT00835952 · 14 enrolled · United States
  3. Mar 18, 20112 phase 1 studies in HealthyAbbVie · NCT01320761, NCT01319916
  4. Oct 17, 2011Phase 1 study in HealthyAbbVie · NCT01462786 · 5 enrolled · United States
  5. Jun 29, 2012Phase 1 study in HealthyAbbVie · NCT01632917 · 24 enrolled · United States
  6. Oct 11, 2012Phase 1 study in HealthyAbbVie · NCT01706679 · 218 enrolled · United States
  7. Apr 22, 2014Phase 3 study in Moderate to Severe Convexity of Submental FatAbbVie · NCT02123134 · 55 enrolled · United States
  8. Jun 6, 2014Phase 2 study in Submental FatAbbVie · NCT02159729 · 205 enrolled · United States, Australia, Canada and more
  9. Jun 12, 2014Phase 3 study in Submental FatAbbVie · NCT02163902 · 224 enrolled · United States, Canada
  10. Mar 4, 2021THERAPIM PTY’s first study: phase 2 study in Ovarian NeoplasmsNew to THERAPIM PTYTHERAPIM PTY · NCT04814875 · 16 enrolled · Australia
  11. Feb 18, 2022Allay Therapeutics’ first study: phase 2 study in Pain, PostoperativeNew to Allay TherapeuticsAllay Therapeutics · NCT05260008 · 112 enrolled · Australia, Canada, United Kingdom
  12. Jan 24, 2025Phase 2 study in Pain, PostoperativeAllay Therapeutics · NCT06799845 · 226 enrolled · United States
  13. Jul 25, 2025Aurobac Therapeutics SAS’ first study: phase 1 study in Healthy ParticipantsNew to Aurobac Therapeutics SASAurobac Therapeutics SAS · NCT07107802 · 24 enrolled · Portugal

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07107802Healthy Participants · Portugal1CompletedAurobac Therapeutics SASOct 24, 202524
NCT06799845Pain, Postoperative · United States2CompletedAllay TherapeuticsOct 3, 2025226
NCT05260008Pain, Postoperative · Australia, Canada, United Kingdom2TerminatedAllay TherapeuticsJan 15, 2024112
NCT04814875Ovarian Neoplasms · Australia2TerminatedTHERAPIM PTYNov 30, 202316
NCT02163902Submental Fat · United States, Canada3CompletedAbbVieJan 2016224
NCT02159729Submental Fat · United States, Australia, Canada and more2CompletedAbbVieDec 2015205
NCT02123134Moderate to Severe Convexity of Submental Fat · United States3CompletedAbbVieAug 201555
NCT01706679Healthy · United States1CompletedAbbVieFeb 2013218
NCT01632917Healthy · United States1CompletedAbbVieJul 201224
NCT01462786Healthy · United States1CompletedAbbVieNov 20115
NCT01320761Healthy · United States1CompletedAbbVie24
NCT01319916Healthy · United States1CompletedAbbVieJan 201110
NCT00835952Characteristics of Subcutaneous Fat · United States1CompletedAbbVieMar 200914
NCT00618709Healthy · United States1CompletedAbbVieDec 200824

How it is read

Names in the registry

  • “ATX-101”, 8 entries
  • “ATX101”, 2 entries
  • “ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)”, 1 entry
  • “ATX-101 (1 mg/cm^2)”, 1 entry
  • “ATX-101 (2 mg/cm^2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.